NEW YORK (GenomeWeb News) – French drug firm Servier has licensed non-exclusive rights to use Cellectis' π10 modified cell lines for high-throughput screening efforts.
The new agreement follows a recently concluded research pact between the firms that began in 2007.
"The cells, gene insertion templates and meganuclease used by Servier are now available as a commercial kit, which provides a reliable, easy-to-use method of creating cell lines specific to drug targets of interest," said Marc Le Bozec, CEO and CFO of Cellectis BioResearch, the subsidiary of Cellectis that markets the kits.
Financial and other terms were not disclosed.